Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Phase I Study of Orally Administered AK0529 in Chinese Healthy Adult Volunteers

NCT03322800 is registered in ClinicalTrials.gov with Shanghai Ark Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03322800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03322800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Phase I Study of Orally Administered AK0529 in Chinese Healthy Adult Volunteers
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2017
Completion date
May 24, 2018
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy